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 CURRENTOPINION The thymus and rheumatology: should we care?
Emilie Coswaya, Graham Andersona, Paul Garsideb, and
Catriona Prendergastb
Purpose of review
The purpose of this review is to discuss the mechanisms of central and peripheral tolerance in relation to T-
cell mediated autoimmunity in rheumatoid arthritis (RA).
Recent findings
The well established association between major histocompatibility complex class II and RA has led us to
understand that T cells, and the adaptive immune response, are important in the pathogenesis of disease.
In order for autoimmune disease to develop, there is a breach of tolerance to self antigen and the
mechanisms of both central and peripheral tolerance aim to prevent this breach of tolerance. Here, we
review evidence from mouse models indicating that alterations in T-cell receptor signalling thresholds during
thymic selection may be linked to the escape of T cells that mediate autoimmune arthritis. In addition, we
summarize the role of dendritic cells and Foxp3þ regulatory T cells in both peripheral and thymic
tolerance, and highlight their relevance to what we know about the aetiology of RA.
Summary
Mechanisms of central tolerance in the thymus and peripheral tolerance are in place to control autoreactive
T cells and to prevent the development of autoimmune disease. WeAQ3 anticipate that a better understanding of
these mechanisms will lead to the development of better, antigen-specific therapeutics to restore tolerance.
Keywords
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INTRODUCTION
The immune system is heavily implicated in the
pathogenesis of rheumatoid arthritis (RA) and there
is a generally accepted view that some type of
‘breach of self-tolerance’ underlies this. However,
the exact mechanisms involved, whether these
relate to differences in central versus peripheral
tolerance, and how this relates to the aetiology of
the disease remains unclear. Here, we discuss how
defects in central and peripheral tolerance may be
involved, how they might be linked and how they
relate to what we know about RA. The ultimate goal
for treatment of autoimmune disease, would be the
development of therapies that promote and restore
self-tolerance in patients. As a result, understanding
central and peripheral tolerogenic mechanisms that
have gone awry in RA will lead to the development
of improved therapeutics that target the restoration
of tolerance.
CENTRAL TOLERANCE MECHANISMS IN
RHEUMATOID ARTHRITIS
The antigen receptors of T cells are randomly
generated to provide the potential to recognize a
wide array of pathogens. As a consequence, self-
reactive T cells are generated. To avoid autoim-
munity, regulatory mechanisms must be in place
to remove and/or control these cells. This
‘immunological tolerance’ is mediated at several
levels and in several cell types. Here, we will focus
on tolerance in T cells in the context of RA.
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Thymic selection
The thymus supports the development of T cells
expressing the ab form of the T-cell receptor. Fol-
lowing their entry at the corticomedullary junction
[1], CD4-CD8-lymphoid precursors randomly
rearrange their T-cell receptor (TCR) genes to maxi-
mize variation within the developing T-cell reper-
toire. Following the induction of CD4AQ4 and CD8
expression [2], these processes generate a large
cohort of CD4þCD8þ thymocytes that express a
wide range of ab form of the TCR specificities.
Owing to the random nature of TCR gene rearrange-
ment, such cells undergo selection processes to
ensure the thymus is biased toward the generation
of self-tolerant T-cells capable of self-major histo-
compatibility complex (MHC) recognition.
During positive selection, recognition of self-
peptides bound to MHC II or MHC I molecules on
cortical thymic epithelial cells ensures the gener-
ation of single positive CD4þ and CD8þ thymo-
cytes, respectively [3]. During this process, newly
selected thymocytes undergo CCR7-mediated
migration to the thymicmedulla (Fig. 1), an import-
ant site for tolerance induction [4]. Here, CD4þ
and CD8þ thymocytes are screened further for
their reactivity to self-antigens, including those
expressed intrathymically as a result of the Aire-
mediated transcription of tissue-restricted antigens
in medullary thymic epithelial cells [5,6]. In the
medulla, dendritic cells also play a key role in thy-
mic tolerance through both cross-presentation of
self-antigens from medullary thymic epithelial
cells as well as migration of self-antigen bearing
dendritic cells from the periphery [7]. Importantly,
the outcome of TCR-MHC interactions within the
medulla is highly dependent upon how strongly
the TCR recognizes self-antigen. High affinity TCR-
mediated interactions result in negative selection
through apoptosis induction, whereas medium
affinity interactions induce expression of the tran-
scription factor FoxP3, and the emergence of the
natural T-regulatory (Treg) lineage [8]. Collectively,
T-cell development involves intrathymic selection
events based upon self-antigen interaction, to
maximize the spectrum of antigen recognition by
newly selected T-cells and also minimize the risk of
generating autoreactive T cells. As a consequence,
factors with the potential to alter TCR signal
strength in response to self-antigen during intra-
thymic development can lead to alterations in thy-
mic tolerance and potentially skew the T-cell
repertoire, leading to autoimmune disease.
Rheumatoid arthritis and altered T-cell
selection
As noted above, RA is a common autoimmune dis-
ease with the cause being linked to a combination of
both genetic and environmental factors [9]. Various
murinemodels have improved our understanding of
the genetic aspects of the disease with a particular
focus on mutations that alter central and peripheral
T-cell tolerance. For instance, under circumstances
where mutations dampen the perception of TCR
affinity strength during selection, high affinity
autoreactive TCRs may escape negative selection.
These instead are allowed to enter into the periph-
eral T-cell pool, where they have a greater propen-
sity to react with self and elicit an autoimmune
phenotype AQ5[8]. There are a number of models and
clinical examples which illustrate this.
The murine SKG model of autoimmune
arthritis
SKG mice, which have a recessive point mutation in
the gene encoding the TCR signalling protein ZAP-
70, are a frequently used model for autoimmune
arthritis. SKG mice have suppressed TCR signal per-
ception allowing selection of a more autoreactive
T-cell repertoire in the thymus that peripherally con-
tributes to the development of autoimmune arthritis
[10]. To illustrate this, autologousmixed lymphocyte
reactions were used to examine the reactivity of
peripheral SKG T cells. These were shown to have
high levels of proliferation and activation to autolo-
gous APCs when compared to control T cells, high-
lighting their autoreactive nature [11]. In addition,
analysis of TCRVb subunit usage showed preferential
expression of certain subfamilies with more
KEY POINTS
" In murine models of RA, alterations in ab TCR
signalling thresholds have been linked to the escape of
autoreactive T cells from central tolerance.
" Peripheral tolerance mechanisms sometimes fail to
control autoreactive T cells leading to development of
RA. Targeting peripheral tolerance mechanisms, as
opposed to central tolerance mechanisms, is a feasible
approach to restore tolerance therapeutically.
" Although both Foxp3þ Treg and dendritic cells enter
the thymus from peripheral tissues to influence
intrathymic tolerance mechanisms, whether alterations
in this process are linked to T-cell mediated
autoimmunity is not known.
" There has been a resurgence of interest in the treatment
of RA via restoration of antigen-specific tolerance, thus
a clearer understanding of the underlying mechanisms
is required.
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autoreactive tendencies in SKG mice than controls
[12]. When these TCRs were isolated, transfected
into bone marrow cells and transferred into Rag2#/
# hosts, autoimmune arthritis was induced, reinforc-
ing the idea that SKG mice have a skewed T-cell
repertoire toward specificities that are more autor-
eactive [13&&]. Collectively, suchobservations suggest
that alterations in the perception of TCR signal
strength may drive the development of arthritis in
SKG mice by altering intrathymic selection of the
developing T-cell repertoire. In addition, intrathymi-
cally generated FoxP3þ Treg from SKG mice show a
defective suppressive capacity when transferred
along with SKG conventional T cells into nude hosts
[12,14], again suggesting that altering the strength of
TCR signalling during intrathymic T-cell selection
events directly impacts upon the T-cell repertoire
that is selected, and increases susceptibility to abnor-
mality [15].
As a consequence of altered thymic selection,
autoreactive peripheral T-cells can respond to self-
antigens expressed by dendritic cells, triggering
their activation and differentiation into function-
ally distinct T-cell subsets. In SKG mice, as with
human RA, the main effector cells have been shown
to be Th17 cells driven by APC-derived IL-6, with IL-
6 deficient SKG mice being devoid of IL-17-produc-
ing CD4 T cells [11]. Interestingly, Th17 cells can be
recruited to joints through CCR6 expression,
attracted by the high CCL20 levels found in arthritic
joints where they are thought to mediate innate cell
activation and joint destruction [16].
Rheumatoid arthritis and PTPN22 variants
PTPN22 AQ6encodes the protein lymphocyte tyrosine
phosphatase (Lyp) or the mouse ortholog Pep, and
is a critical negative regulator of TCR signal
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FIGURE 1. Regulation of central and peripheral tolerance. The organization of the thymus into cortex and medulla ensures
that thymic selection events take place in a stepwise fashion. In the medulla, tolerance-inducing events coordinated by
medullary thymic epithelial cells and dendritic cells help to remove potentially autoreactive specificities from the newly
produced T-cell pool, and also result in the generation of FoxP3þ regulatory T cells. In peripheral tissues, several immune-
regulatory products of DC and Treg have been linked to the control of effector T cells that mount responses to self-antigens.
Perhaps significantly, the thymus also acts as a site that supports T cell and dendritic cell populations that enter from peripheral
tissues, and evidence suggests a role for thymus recirculation in the control of T-cell tolerance. DN: CD4-CD8-, DP:
CD4þCD8þ; SP CD4þ or CD8þ.
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transduction upstreamof ZAP-70. A single nucleotide
polymorphism in the protein tyrosine phosphatase
N22 producing a PTPN22 variant (R620W) has been
shown to support the progression of autoimmune
disease such as type I diabetes and it was further
suggested to be the second strongest genetic risk
factor for RA, second to HLA variants in humans
[17,18]. Interestingly, this PTPN22 variant (R620W)
has been suggested to be a gain of functionmutation,
linked to reduced TCR signalling during intrathymic
T-cell selection and high affinity self-reactive T-cells
in the periphery [17,19]. However, other studies have
reported that the consequence of PTPN22 polymor-
phismsmay be a decrease in phosphatase activity and
an increase in TCR signalling [20].
Despite this discrepancy, a variant of Lyp
(Lyp620W) which is encoded by PTPN22 has been
associated with autoimmune disease in humans. Its
affect on disease development can be studied using
mice expressing the Lyp variant homolog Pep619W.
Analysis of thesemice carryingOT-II TCR ormale H-
Y antigen TCR transgenes showed increasedCD4þ T-
cell positive selection, proliferation of the memory/
effector T-cell pool, but no alteration in negative
selection indicating a complex requirement for
functional Lyp in ensuring appropriate TCR signal-
ling during T-cell selection [20]. In addition, a lack
of PTPN22 expression was investigated in mice with
regards to T-regulatory cells, which have been
shown to express higher levels of PTPN22 than
conventional T cells [21]. Interestingly, when com-
pared with WT mice, Ptpn22-/- mice showed signifi-
cant increases in Treg and their precursor
populations [21], suggesting alterations in TCR sig-
nalling are able to affect the balance between con-
ventional and Foxp3þ Treg development, which
might further affect autoimmune status.
PERIPHERAL TOLERANCE MECHANISMS
IN RHEUMATOID ARTHRITIS
Although mutations within the thymus can alter T-
cell selection and skew theT-cell repertoire towardan
autoreactive nature, under normal circumstances,
the selection processes that are in place to prevent
autoreactive T cells escaping from the thymus are still
not 100% effective. As a result, there are always some
autoreactive T cells that do escape, undetected, into
the periphery. For this reason, the mechanisms of
peripheral tolerance are vital to prevent the develop-
ment of autoimmune disease. In this section, various
mechanismsofperipheral tolerancewillbediscussed.
These include regulation via Treg, and tolerogenic
dendritic cells as well as their relevance to RA, and
how these mechanismsmay fail in RA patients, lead-
ing to a breakdown of tolerance.
T-regulatory cells
Treg are known to be vital for the maintenance
of immunological tolerance (reviewed in [22,23]).
Along with natural CD4þCD25þFoxP3þ Treg
(nTreg), other regulatory populations include indu-
cible CD4þFoxP3þ Treg (iTreg), which develop in
the periphery after induction of FoxP3 expression,
and CD4þFoxP3- type 1 regulatory T cells (Tr1).
FoxP3 has been shown to be vital for the develop-
ment and suppressive function of Treg [24] as in its
absence aggressive autoimmune disease develops as
self-tolerance is broken [25–29]. Treg manifest their
suppressive function through various mechanisms
including direct cell-to-cell contact, or indirectly
through the secretion of anti-inflammatory cyto-
kines (e.g. IL-10, IL-35, or TGF-b) as IL-10 or IL-35
deficient have an impaired suppressive capacity
[30,31]. The secretion of TGF-b can induce the
development of further Treg fromCD4þCD25- naı¨ve
T cells [32,33]. Treg can also act by reducing the
functions of APCs by inhibiting CD80 and CD86
expression, via a CTLA-4 dependent mechanism
[34–36].
Murine studies, using collagen-induced arthri-
tis as a model of RA, have shown that the
depletion of Treg using anti-CD25 resulted in
increased disease severity [37], and reduced disease
severity was observed when Treg were introduced
by adoptive transfer [38]. Treg from RA patients
have been shown to be defective in their ability to
suppress proinflammatory cytokine production by
CD4þ T cells, although they can efficiently sup-
press their proliferation; this defect in their sup-
pressive abilities may be because of a defect in
CTLA-4 expression and function [39–41]. B cells
are known to have a key pathogenic role in the
aetiology of RA, as evidenced by the efficacy of
rituximab treatment in RA patients [42,43]. In
relation to this, Treg have been shown to regulate
the pathogenic function of B cells during inflam-
mation both in murine models and in RA itself
[44,45].
Tr1 cells mediate their suppressive function
through the secretion of IL-10 and TGF-b and are
known to suppress both immune and autoimmune
responses [46]. A population of antigen-specific IL-
10-producing Tr1 cells has been identified in the
blood of RA patients [47] indicating theymay have a
role in maintenance of peripheral tolerance in RA.
The transfer of Tr1 cells in murine models of RA was
found to be beneficial, reducing the incidence and
severity of arthritis when administered before and
after induction of disease [48]. The Tr1 cell popu-
lation could, therefore, be a promising target for the
restoration of tolerance in autoimmune diseases,
including RA.
Immunopathogenesis and treatment of autoimmune diseases
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Role of dendritic cells in the regulation of
peripheral tolerance
Dendritic cells are vital for the induction of the
inflammatory immune response against, for
example, invading pathogens. In addition to this,
dendritic cells are also central to immune regulation
and inducing and maintaining tolerance (Fig. 1), as
demonstrated by the development of fatal spon-
taneous autoimmune disease following dendritic
cell depletion [49].
‘Tolerogenic’ dendritic cells are generated
through the incomplete maturation of dendritic
cells, as occurs during the steady state. These tol-
erogenic dendritic cells present antigen to T cells in
the absence of adequate costimulatory signals and
result in the maintenance of peripheral tolerance
through mechanisms including T-cell deletion,
unresponsiveness or anergy [50], and the induction
of regulatory T cells [51]. These effects are mainly
attributed to the production of anti-inflammatory
cytokines, for example, IL-10 and TGF-b, and the
expression of downregulatory/inhibitory markers,
for example, PDL-1 and PDL-2 (reviewed in [52,53]).
Restoring tolerance through the use of immu-
nomodulatory tolerogenic dendritic cells in RA has
become an exciting line of therapeutic potential.
Studies in murine CIA have shown tolerogenic den-
dritic cells to be highly effective. Introducing in-
vitro derived type-II collagen-pulsed tolerogenic
dendritic cells into arthritic CIA mice reduced the
severity of the disease, reduced the inflammatory
environment (lower levels of Th17 cells) and
increased the anti-inflammatory environment
through increased levels of IL-10 producing T-cells
[54]. The generation of tolerogenic dendritic cells
from RA patients has been investigated [55] and
their safety and efficacy as a therapy is currently
being determined in clinical trials [56]. Cellular
therapies like tolerogenic dendritic cells or the
manipulation of dendritic cells in vivo to induce a
more tolerogenic population could be a potential
and feasible therapy for RA patients in the future.
In addition to tolerogenic dendritic cells being
able to regulate immune responses, different subsets
of dendritic cells may have different roles in auto-
immune disease. Using a novel breach of self-toler-
ance murine model of arthritis [57], we have shown
that plasmacytoid dendritic cells have an anti-
inflammatory role [58]. By contrast, conventional
dendritic cells have a more proinflammatory role.
Their depletion resulted in reduced severity of dis-
ease as well as reduced anticollagen responses [59].
Interestingly, peripheral dendritic cell homing to
the thymus provides a source of peripheral antigens
for tolerance induction in the steady state [60,61].
Whether the onset of autoimmune reactions alters
this process, and so impacts on intrathymic toler-
ance mechanisms is not known.
Recirculation of peripheral T cells back to the
thymus
It has been known for some time now that periph-
eral T cells, including both conventional and
Foxp3þ Treg, can home back to the thymus, which
challenges the view that movement out of the thy-
mus is unidirectional (Fig. 1). The first evidence
showed labelled lymph node cells transferred into
syngeneic hosts could be found within the thymus
in both adult and neonatal hosts [62]. In the mouse,
mature peripheral T cells that migrate into the thy-
mus resemble activated, or previously activated,
CD44hi T cells which appear to preferentially enter
over naı¨ve T cells [63–65] (reviewed in detail [66]).
The question remains as to what function these
recirculating peripheral lymphocytes have in the
thymus. There is emerging evidence that these cells
are able to alter central tolerance and induce the
deletion of thymic APC populations in an antigen
specific manner [67]. In addition, very recently it
has been shown that peripheral Treg can also recir-
culate back to the thymus and once there they
suppress the development of new Treg through
the inhibition of IL-2 [68&&]. In the same study,
evidence of the reentry of mature T cells and Treg
into the human thymus was also found. In the
setting of autoimmune disease and RA, this could
be an interesting mechanism for silencing autoreac-
tive T cells. Moreover, despite having sufficient
numbers of progenitor cells [69–71], RA patients
exhibit impaired thymic function as indicated by
fewer recent thymic emigrants. Whether this is
linked to changes in peripheral T-cell recirculation
back to the thymus caused by ageing and/or RA is
not clear.
CONCLUSION
The thymus represents a key site for the generation
of abT cells that play an essential role in immune
responses. However, the removal of autoreactive T
cells from the developing TCR repertoire via intra-
thymic selection mechanisms is incomplete, which
is a significant factor in relation to the onset of T-cell
mediated autoimmune diseases. To combat this,
peripheral tolerance mechanisms involving modu-
lation of dendritic cell function and Foxp3þ Treg are
in place. In RA, evidence suggests that a breakdown
in T-cell tolerance takes place. However, whether
this maps to altered T-cell responses in either in the
thymus or within peripheral tissues, is not clear.
The thymus and rheumatology Cosway et al.
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Perhaps significantly, both sites are linked not only
by the conventional T cells, Foxp3þ Treg and den-
dritic cell subsets they contain, but also by traffick-
ing of these cell types between each site. How
such processes impact on the maintenance of toler-
ance, and its breakdown, is not understood. We
propose that adopting an overarching approach to
studying tolerance regulation at sites of T-cell pro-
duction and effector function will provide new
opportunities to better understand tolerance main-
tenance and breakdown, and inform future strat-
egies for immune intervention.
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